1-20 of 60
Lin LIU
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study

Free
Ting Niu, Lin LIU, Huijing Wu, Keshu Zhou, Wei Yang, Li Wang, Shu Cheng, Jie Wang, Jinrong Yang, Fei Li, Shiyong Zhou, Yanhong Tong, Ke Tan, Adrian Rui Liang, linyu yang, Lijuan Chen, Wei Li Zhao
Journal: Blood
Blood (2025) 146 (Supplement 1): 5415.
https://doi.org/10.1182/blood-2025-5415
Published: 2025
Journal Articles

Lipo-MIT-based bridging therapy enables effective CAR-T treatment in high-risk relapsed or refractory B-cell lymphoma

Free
Yun Kang, Danying Liao, Wei Xie, Lin Liu, Yinqiang Zhang, Heng Mei
Journal: Blood
Blood (2025) 146 (Supplement 1): 5935.
https://doi.org/10.1182/blood-2025-5935
Published: 2025
Journal Articles

Inotuzumab ozogamicin vs blinatumomab bridging optimization and second CD19 CAR-T efficacy in Relapsed/Refractory B-ALL

Free
Lin Liu, Danying Liao, Weijiayi Wang, Wei Xie, Jia Xu, Yinqiang Zhang, Fen Zhou, Heng Mei
Journal: Blood
Blood (2025) 146 (Supplement 1): 2398.
https://doi.org/10.1182/blood-2025-2398
Published: 2025
Journal Articles

BCMA-targeted CAR T cells for multi-refractory primary immune thrombocytopenia: A pilot study

Free
Jinhui Shu, Min Xu, Wei Xie, Lin Liu, Qiuzhe Wei, Hongjian Li, Jishuai Zhang, Yu Hu, Heng Mei
Journal: Blood
Blood (2025) 146 (Supplement 1): 1267.
https://doi.org/10.1182/blood-2025-1267
Published: 2025
Journal Articles

Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in advanced solid tumors: A multicenter, randomized, double-blind, placebo-controlled phase III trial

Free
ShuKui Qin, Yanqiao Zhang, Hongli Li, Yong Mao, Wenhui Yang, Zhong Xie, Yanyan Liu, Lixin Wan, Yanjun Zhang, Xizhi Zhang, Xinghua Han, Lizhu Lin, Jun Yao, Yong Li, Yun Wu, Lin Liu, Mingjun Zhang, Guixiang Weng, Junyan Yu, Tao Si, Li Zhang, Zhenyang Liu, Guoping Zhang, Yong Li, Jin Xia, Xiaoli Liao, Qingshan Li, Jin Lu, Tienan Yi, Na Li, Zhitu Zhu, Xiaoyan Lin, Kaijian Lei, Jie Ma, Donglu Zhao, Junye Xiong, Runzi Li, Xiang Lin, Qian Tang, Jun Ma
Journal: Blood
Blood (2025) 146 (Supplement 1): 1256.
https://doi.org/10.1182/blood-2025-1256
Published: 2025
Journal Articles

Robust assessment of early MRD levels could further improve treatment outcomes in low-risk patients of pediatric acute lymphoblastic leukemia: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL Study

Free
Hsi-Che Liu, Shiann-Tarng Jou, Shih-Hsiang Chen, Tang-Her Jaing, Ting-Chi Yeh, Jiann-Shiuh Chen, Kang-Hsi Wu, Shih-Chung Wang, Chih-Cheng Hsiao, Te-Kau Chang, Hsiu-Hao Chang, Hsiu-ju Yen, Fang-Liang Huang, Shu-Huey Chen, Shang-Hsien Yang, Yen-Lin Liu, Shyh-Shin Chiou, Chao-Ping Yang, Lee-Yung Shih, Dong-Tsamn Lin
Journal: Blood
Blood (2025) 146 (Supplement 1): 1550.
https://doi.org/10.1182/blood-2025-1550
Published: 2025
Journal Articles

Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients

Free
Lijuan Chen, Na Gao, Wei Yang, Qike Zhang, Hu Zhu, Zhihua Zhang, Lin LIU, Yong Wu, Jinxiao Yao, Zhenfang Liu, Zhenya Hong, Yanping Song, Xiaoyu Zhu, Jia Miao, Jinrong Yang, Ke Tan, Adrian Rui Liang, Zefeng Xu, Ting Niu, Zhijian Xiao
Journal: Blood
Blood (2025) 146 (Supplement 1): 908.
https://doi.org/10.1182/blood-2025-908
Published: 2025
Journal Articles

Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma

Free
Yinqiang Zhang, Lin Liu, Liman Su, Qiaolin Liu, Wei Xie, Heng Mei
Journal: Blood
Blood (2025) 146 (Supplement 1): 7261.
https://doi.org/10.1182/blood-2025-7261
Published: 2025
Journal Articles

Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study

Free
Taiyuan Zhang, Yingying Wu, Zhipeng Cheng, Ao Zhang, Lin Liu, Lu Zhang, Danying Liao, Wei Xie, Fang Liu, Guohui Cui, Yu Hu, Heng Mei, Jun Fang
Journal: Blood
Blood (2025) 146 (Supplement 1): 7207.
https://doi.org/10.1182/blood-2025-7207
Published: 2025
Journal Articles

Autologous CD19-directed CAR-T exhibit promising safety and efficacy in refractory primary immune thrombocytopenia

Free
Mengli Xu, Shiqi Li, Zhi Yang, Lin Liu, Zhongtao Yuan, Yu Li, Yingzi Zhang, Juan Hong, Lihui Peng, Xuejuan Zhang, Lihua Zhang, Yingnian Chen, Qingying Zang, Qianzhen Zhang, Junjie Shen, Xiaoping Li, Yunyan Li, Yancheng Dong, Youcheng Wang, Dingsong Zhang, Linling Wang, Meiling Wang, Wei Zhu, Jiong Hu, Cheng Qian, Sanbin Wang
Journal: Blood
Blood (2025) 146 (Supplement 1): 4175.
https://doi.org/10.1182/blood-2025-4175
Published: 2025
Journal Articles

SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma

Free
Chan Cheah, Monique Menzies Wojtowicz, Dok Hyun Yoon, Dehui Zou, Rebecca Auer, Won-Seog Kim, Bor-Sheng Ko, Hung-Lin Liu, Lorenzo Falchi, Yuqin Song, Pier Luigi Zinzani, Daisuke Ennishi, Francesc Garcia Pallarols, Xiaofei Chen, Stefanie Meyer, Ricardo Espinola, Mihail Obrocea, Franck Morschhauser, Dai Maruyama, Tae Min Kim
Journal: Blood
Blood (2025) 146 (Supplement 1): 3614.
https://doi.org/10.1182/blood-2025-3614
Published: 2025
Journal Articles

Real-world factor VIII trough levels of severe-type people with Hemophilia A (PwHA) on efanesoctocog alfa prophylaxis: Interpersonal variation, clinical correlates and predictors

Free
Chia-Yau Chang, Tefu Weng, Shiue-Wei LAI, Der-Shiun Wang, Jia-Ruey Tsai, Yen-Lin Liu, Chen-Hua Tsai, Wan-Ling Ho, Shu-Hsia Hu, Yeu-Chin Chen
Journal: Blood
Blood (2025) 146 (Supplement 1): 3063.
https://doi.org/10.1182/blood-2025-3063
Published: 2025
Journal Articles

Efficacy and safety of NTQ5082 monotherapy in complement-inhibitor-Naïve patients with paroxysmal nocturnal hemoglobinuria: A proof-of-concept, multicenter, randomized, open-label phase 2 study

Free
Fengkui Zhang, Hongyan Tong, Linghui Xia, Li Zhang, Gaixiang Xu, Lin Liu, Yumeng Zhou, Rongfeng Zhou
Journal: Blood
Blood (2025) 146 (Supplement 1): 982.
https://doi.org/10.1182/blood-2025-982
Published: 2025
Journal Articles

Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data

Free
Xi Dou, Yiying Xiong, Lanxiang Liu, Xiaoqiong Tang, Hongbin Zhang, Xin Wang, Jianbin Chen, Lin Liu, Li Wang
Journal: Blood
Blood (2025) 146 (Supplement 1): 8083.
https://doi.org/10.1182/blood-2025-8083
Published: 2025
Journal Articles

Mitochondrial mass in pre-lymphodepletion T cells predicts early response to CAR-T therapy in relapsed/refractory non-Hodgkin lymphoma

Free
Li Cai, Yun Kang, Lin Liu, Wei Xie, Mengyi Du, Heng Mei
Journal: Blood
Blood (2025) 146 (Supplement 1): 4114.
https://doi.org/10.1182/blood-2025-4114
Published: 2025
Journal Articles

Clinical outcomes and novel therapeutic strategies in adult patients with MLL-rearranged acute lymphoblastic leukemia: A monocentric retrospective analysis

Free
Lin Liu, Yinqiang Zhang, Weijiayi Wang, Wei Xie, Mengyi Du, Fen Zhou, Heng Mei
Journal: Blood
Blood (2025) 146 (Supplement 1): 6890.
https://doi.org/10.1182/blood-2025-6890
Published: 2025
Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Free
Wei Li Zhao, Jun Zhu, Pengpeng Xu, Yuqin Song, Jianzhen Shen, Qingqing Cai, Hui Zhou, Liling Zhang, Ying Xiang, Xiuhua Sun, Wei Yang, Zhihua Yao, Hongmei Jing, Shujuan Wen, Jie Jin, Hongwei Xue, Hong Cen, Kaiyang Ding, Zhengming Jin, Lihong Liu, Xiaojing Xing, Lanfang Li, Ming Hou, Lin LIU, Mingzhi Zhang, Wenyu Li, Ou Bai, Ru Feng, Zunmin Zhu, Huijing Wu, Liping Su, Li Gao, Fei Li, Wenrong Huang, Peng Liu, Xiaojing Yan, Ying Zhao, Hang Su, Xielan Zhao, Rong FU, Hong Liu, Wenyu Shi
Journal: Blood
Blood (2025) 146 (Supplement 1): 475.
https://doi.org/10.1182/blood-2025-475
Published: 2025
Journal Articles

An update: Safety and efficacy of GPRC5D targeting CAR-T cell therapy in relapsed/refractory multiple myeloma patients

Free
Shiqi Li, Yongwei Zheng, Zhongtao Yuan, Lin Liu, Yu Li, Xiaoping Li, Yingnian Chen, Qingying Zang, Lihua Zhang, Mengli Xu, Ping Yin, Lvzhe Chen, Guangchao Li, Wen Ding, Kaikai Zeng, Donghui Ma, Chunfu Li, Min Luo, Sanbin Wang
Journal: Blood
Blood (2025) 146 (Supplement 1): 5854.
https://doi.org/10.1182/blood-2025-5854
Published: 2025
Journal Articles

Bendamustine combined with fludarabine/cyclophosphamide as a enhanced lymphodepletion regimen demonstrates favorable efficacy and safety in CAR-T therapy for extranodal/bulky R/R B-cell lymphoma

Free
Cong Lu, Danying Liao, Lin Liu, Wei Xie, Yun Kang, Yinqiang Zhang, Heng Mei
Journal: Blood
Blood (2025) 146 (Supplement 1): 1950.
https://doi.org/10.1182/blood-2025-1950
Published: 2025
Journal Articles

Factor VIII (FVIII) Trough Levels of Real-World Severe-Type People with Hemophilia a (PwHA) on rFVIII-Fc Prophylaxis: Clinical Correlates and Effects on Perceivable Bleeding Outcomes

Free
Chia-Yau Chang, Shiue-Wei Lai, Mei-Mei Cheng, Yen-Lin Liu, Jia-Ruey Tsai, Chen-Hua Tsai, Wan-Ling Ho, Chao-Neng CHENG, Shu-Hsia Hu, Yeu-Chin Chen
Journal: Blood
Blood (2024) 144 (Supplement 1): 3966.
https://doi.org/10.1182/blood-2024-200872
Published: 2024